Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - Paratek Pharmaceuticals, Inc. | prtk-ex991_6.htm |
UNITED STATES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): March 27, 2017
PARATEK PHARMACEUTICALS, INC.
(Exact name of registrant as specified in charter)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Delaware |
|
001-36066 |
|
33-0960223 |
|
|
(State or Other Jurisdiction of Incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer Identification No.) |
|
|
75 Park Plaza Boston, MA |
|
02116 |
|||
|
(Address of principal executive offices) |
|
(Zip Code) |
|||
(617) 807-6600
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
|
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01 Regulation FD Disclosure.
On March 27, 2017, Paratek Pharmaceuticals, Inc. and Allergan plc issued a joint press release announcing top-line data from Allergan plc’s Phase 3 clinical trials of sarecycline for the treatment of acne. A copy of this press release is attached hereto as Exhibit 99.1.
The information in this Current Report on Form 8-K is being furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.
Item 9.01 Financial Statements and Exhibits.
|
|
|
|
(d) |
Exhibits |
|
|
|
|
|
|
|
|
|
Exhibit No. |
|
Description |
|
|
|
|
|
99.1 |
|
Press Release dated March 27, 2017 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PARATEK PHARMACEUTICALS, INC. |
||||
|
|
|
|
||||
|
Date: March 27, 2017 |
|
By: |
/s/ William M. Haskel |
|||
|
|
|
|
William M. Haskel |
|||
|
|
|
|
SVP, General Counsel and Corporate Secretary |
|||
|
|
|
|
|
|
|
|
|
Exhibit No. |
|
Description |
|
|
|
|
|
99.1 |
|
Press Release dated March 27, 2017 |